Delivery Order SPE2DB22D2206-SPE2DB25FJM64
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $52,487.80 by the Defense Logistics Agency on August 28, 2025, for the supply of Revlimid 25 mg capsules (100-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 19, 2025, and will be performed at the awardee's Conshohocken location. The contract carries no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at approximately $51.7K to AmerisourceBergen Drug Corp for the supply of Revlimid 10 mg capsules (28-count units). This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a non-competitive procurement executed under an existing contract vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Revlimid 25 mg capsule medication. The $20,562.98 contract has an ultimate completion date of April 24, 2024 and was awarded on April 3, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to...
- The Defense Logistics Agency awarded a delivery order valued at $52,575.49 to AmerisourceBergen Drug Corp for 100 capsules of REVLIMID 10 mg on August 8, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply framework with DLA. The pharmaceutical product will be delivered to the company's corporate office location in...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of REVLIMID 20 MG CAPSULE 100S. The award, valued at $89,155.06, has an ultimate completion date of October 8, 2024. AmerisourceBergen holds multiple Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, including a $999,999,999 IDC with DLA Troop Support Medical for a comprehensive range of medical commodities. This...
- This federal contract award is for the delivery of the pharmaceutical drug Revlimid (10 mg capsule, 28-count) to the Defense Logistics Agency (DLA). The $23,330.28 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor. The contract, which has no set-aside designation, has a completion date of June 5, 2024. AmerisourceBergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was issued by the Defense Logistics Agency (DLA) Troop Support Medical for the delivery of 4557530338 - REVLIMID 5 MG CAPSULE 100S. The $160,303.95 firm fixed price delivery order contract has a completion date of July 5, 2022 and does not have a set-aside designation. Amerisourcebergen Drug Corp is a prime contractor that has received numerous federal contract awards from DLA to supply...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $49,926.80, is for the delivery of the prescription medication Revlimid 10 mg capsules. It is a firm-fixed price, non-set-aside contract with a performance period through May 1, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of REVLIMID 10 MG CAPSULE 28S. The contract has a ceiling value of $124,817.00 and is a firm-fixed-price arrangement with a period of performance through July 1, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $199,707.28, is a delivery order for the supply of REVLIMID 10 MG CAPSULE 28S, a prescription medication. The contract is a firm fixed-price, non-set-aside award with a performance period through May 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJM64Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $52,487.80 by the Defense Logistics Agency for the supply of Revlimid 25 mg capsules (100-count units). The award, issued on August 19, 2025, with an ultimate completion date of September 10, 2025, represents a firm fixed-price delivery order with no set-aside designation. This contract was competitively awarded and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates significant capability in fulfilling specialized pharmaceutical procurement requirements for the Defense Health Agency and other federal healthcare systems across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $52.5k | 8/19/25 |